INmune Bio Inc. Common stock (INMB)
Stock · NASDAQ · Health Care
$1.57as of 10/16/2026
Price chart
Active signals
INMB Signal Track Record
How signals performed across all stocks →What INMB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +0.2% | 51% | September 16, 2026 |
| Bollinger Band Breakout | 24 | -10.3% | 33% | June 29, 2026 |
| Bollinger Band Breakdown | 18 | +7.8% | 67% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +4.4% | 67% | April 8, 2025 |
| Any 20-session window (baseline) | -2.1% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INMB
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk m…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 21
- Website
- www.inmunebio.com/
Fundamentals
- 1-day range
- $1.56$1.68
- Market cap
- $50.78M
- P/E (trailing)
- —
- P/E (forward)
- -3.65
- EPS (trailing)
- $-0.69
- Dividend yield
- —
- Beta
- 0.91
- Avg. volume
- 343.0K
How INmune Bio Inc. Common stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 27, 2025 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
INmune Bio Inc. Common stock Competitors
Chosen by industry and closest market cap.
- INMBINmune Bio Inc. Common stock$1.57▼ 4.85%Market cap $50.78MP/E —$1.09$2.6
- TCRXTScan Therapeutics Inc. Common Stock$0.231▼ 3.35%Market cap $49.88MP/E —$0.2243$2.57
- OKYOOKYO Pharma Limited Ordinary Shares$1.41▼ 1.40%Market cap $51.94MP/E —$1.26$3.2
- TILInstil Bio Inc. Common Stock$5.91▼ 3.59%Market cap $49.37MP/E —$5.67$21.64
- ATYRaTyr Pharma Inc. Common Stock$0.174▼ 5.43%Market cap $49.22MP/E —$0.2$1.11
- EXOZeXoZymes Inc. Common Stock$4.09▲ 2.25%Market cap $47.57MP/E —$4.35$18.4
- INKTMiNK Therapeutics Inc. Common Stock$9.41▼ 5.33%Market cap $54.80MP/E —$8.48$16.93
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INMB INmune Bio Inc. Common stock | $50.78M | — | $1.57 | ▼ 4.85% | $1.09$2.6 |
| TCRX TScan Therapeutics Inc. Common Stock | $49.88M | — | $0.231 | ▼ 3.35% | $0.2243$2.57 |
| OKYO OKYO Pharma Limited Ordinary Shares | $51.94M | — | $1.41 | ▼ 1.40% | $1.26$3.2 |
| TIL Instil Bio Inc. Common Stock | $49.37M | — | $5.91 | ▼ 3.59% | $5.67$21.64 |
| ATYR aTyr Pharma Inc. Common Stock | $49.22M | — | $0.174 | ▼ 5.43% | $0.2$1.11 |
| EXOZ eXoZymes Inc. Common Stock | $47.57M | — | $4.09 | ▲ 2.25% | $4.35$18.4 |
| INKT MiNK Therapeutics Inc. Common Stock | $54.80M | — | $9.41 | ▼ 5.33% | $8.48$16.93 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Juda Scott · July 2, 2026 · X14.8K @ $0.125
- Juda Scott · July 2, 2026 · Option Exercise14.8K @ $1.4
- Lowdell Mark William · July 2, 2026 · X7.2K @ $0.125
- Lowdell Mark William · July 2, 2026 · Option Exercise7.2K @ $1.4
- Moss David J · July 2, 2026 · X9.0K @ $0.125
- Moss David J · July 2, 2026 · Option Exercise9.0K @ $1.4
Institutional Ownership
March 31, 2026
- Total shares held
- 5.16M
- Total value held
- $5.83M
- Institutional holders
- 78
- Unknown1.19M
- Unknown687.0K
- Unknown495.0K
- Unknown290.9K
- Unknown270.3K
- Unknown253.3K
- Unknown243.2K
- Unknown231.6K
- Unknown203.2K
- Unknown184.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
INmune Bio Announces Attendance at 2026 Maxim Growth Summit
INmune Bio said it will attend the 2026 Maxim Growth Summit. The event is a platform for biotech companies to meet investors and partners. Attendance may raise the company’s profile and open new collaboration opportunities. The stock is currently trading near the lower end of its 52‑week range.
INmune Bio Announces Attendance at 2026 Maxim Growth Summit. INmune Bio said it will attend the 2026 Maxim Growth Summit. The event is a platform for biotech companies to meet investors and partners. Attendance may raise the company’s profile and open new collaboration opportunities. The stock is currently trading near the lower end of its 52‑week range.